300406 九强生物
2026/06 - 中期2025/122024/122023/122022/12

盈利能力分析
净资产收益率 ROE (%)5.7024.79913.71614.97312.663
总资产报酬率 ROA (%)4.2383.57810.02710.7018.712
投入资产回报率 ROIC (%)4.3903.72410.54811.2699.230

边际利润分析
销售毛利率 (%)80.86479.34978.49874.66474.590
营业利润率 (%)35.45417.40937.61834.09930.147
息税前利润/营业总收入 (%)38.57220.43339.69336.50432.932
净利润/营业总收入 (%)30.99214.05732.35929.97626.108

收益指标分析
经营活动净收益/利润总额(%)102.833180.20397.11799.276104.893
价值变动净收益/利润总额(%)3.0505.1371.5493.4984.245
营业外收支净额/利润总额(%)-0.0300.114-0.542-0.054-1.365

偿债能力分析
流动比率 (X)11.85112.8409.2807.8566.936
速动比率 (X)10.76611.7488.4867.0836.199
资产负债率 (%)26.47525.12825.93228.09629.138
带息债务/全部投入资本 (%)22.94821.72521.62623.25125.034
股东权益/带息债务 (%)332.852357.066358.889327.415296.779
股东权益/负债合计 (%)278.169298.370286.005256.127243.373
利息保障倍数 (X)12.3276.80217.42415.06410.321

营运能力分析
应收账款周转天数 (天)270.080277.174236.375218.230229.676
存货周转天数 (天)263.485262.228227.297183.318221.139